ALLMedicine™ Eosinophilic Gastroenteritis Center

Jun 25th, 2022 - Eosinophilic gastrointestinal disorders (EGIDs) are inflammatory conditions of the gastrointestinal tract that are characterized by tissue eosinophilia and end-organ dysfunction or damage. Primary EGIDs are associated with atopy and other allergic...

May 26th, 2022 - Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U. S.

May 17th, 2022 - The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.

May 7th, 2022 - A 34 year-old previously healthy Japanese woman presented with a 4 year history of migratory arthralgia, chronic diarrhea, mild fever, and 10 kg weight loss. She was initially misdiagnosed with seronegative arthritis, followed by eosinophilic gast...

Feb 20th, 2022 - Substantial heterogeneity in terminology used for eosinophilic gastrointestinal diseases (EGIDs), particularly the catchall term "eosinophilic gastroenteritis," limits clinical and research advances. We aimed to achieve an international consensus ...

May 17th, 2022 - The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.

Feb 7th, 2022 - Eosinophilic gastrointestinal disorders (EGIDs) comprise a family of disorders that includes Eosinophilic Esophagitis (EoE), Eosinophilic Gastritis (EG), Eosinophilic Gastroenteritis (EGE), and Eosinophilic Colitis (EC). The natural history of EGI...

Sep 28th, 2021 - This retrospective chart review study will analyze the demographics, medical history, clinical features, and pathological data of patients with Eosinophilic Gastrointestinal Disorders (EGIDs) other than Eosinophilic Esophagitis (EoE) alone, includ...

Aug 3rd, 2021 - This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic Gastritis and/or ...

Jan 7th, 2021 - This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.

May 26th, 2022 - Eosinophilic GI diseases (EGIDs) often overlap with other eosinophil-associated diseases (EADs), which leads to greater health care costs, according to an analysis of the U. S.

Feb 18th, 2022 - Immune-mediated inflammatory diseases (IMIDs) of the gastrointestinal (GI) tract, with features that often mimic each other, commonly present clinical challenges. But key characteristics can help distinguish the most common – inflammatory bowel di.

Oct 23rd, 2017 - ORLANDO – Patients with eosinophilic esophagitis had a ninefold increased prevalence of celiac disease, compared with the general public, in a review of more than 35 million U. S.

May 18th, 2017 - Answer: Eosinophilic gastroenteritis Colonic (Figure D) and esophageal (Figures E and F) mucosal biopsies were obtained, which showed dense eosinophilic infiltrate of the esophageal and rectal submucosa and the rectal deep mucosa. These findings w.

Feb 24th, 2017 - Once the diagnosis of idiopathic eosinophilic gastroenteritis has been confirmed, the mainstay of treatment is primarily oral glucocorticoids, such as prednisone, to halt the inflammatory process and control symptoms. Budesonide has also been used...